To the editor. Medroxyprogesterone acetate (MPA)is a derivative of 17-medroxyprogesterone with strong progestational activity and is used for the treatment of advanced breast cancer and endometrial cancer. Other than progestational activity, medroxyprogesterone acetate has a weak glucocorticoid-like effect (1) and it is known to induce impairment of glucose tolerance and hyperglycemia whengiven at high doses (2). Oral hypoglycemic agents such as sulphonylurea, biganide, and a-glucosidase inhibitor are often ineffective in the treatment of steroid-induced diabetes, and insulin therapy is required. We report two type 2 diabetic patients with MPAtreatment whose deterioration of
Troglitazone
(400 mg/day) jHHH|j The first case involved a 70-year-old womanwho was diagnosed as having type 2 diabetes at the age of 64. She underwent a hysterectomy for endometrial cancer in September 1994 at 65 years of age. Before the operation, her height was 146 cm, weight was 58 kg and her HbA,c was 7.9%. After surgery, she was prescribed 600 mg per day MPA.Her blood glucose control deteriorated after MPAadministration (Fig. 1, upper set) . In January 1997, glibenclamide was prescribed and HbAlc decreased to 9.1%, but her blood glucose increased again. Because she could not tolerate cx-glucosidase inhibitors, metoformin was added in December1997, but it was not effective. In June 1998, her body weight was 56.5 kg and HbAlc was 13.2%. Her urinary C-peptide immunoreactivity (CPR) was 73.6 Jig/day and fasting serum immunoreactive insulin (IRI) was 9 |xU/ml. Troglitazone was prescribed at a dose of 400 mg per day. Her Hb AJC subsequently decreased. Her blood glucose and serum level of IRI increased again after discontinuation of troglitazone, and these changes were improved whenMPAtherapy was complete.
The second case involved a 64-year-old womanwho was diagnosed as having type 2 diabetes at the age of 58. A hysterectomy was performed for endometrial cancer in May1995 at 60 years of age. She was treated with diet therapy alone and her hemoglobin A1Cwas 6.4% before surgery. After the hysterectomy, 600 mg a day of MPAwas prescribed. Her blood glucose control subsequently deteriorated (Fig. 1, lower set) . In February 1997, her height was 161 cm, weight was 62 kg, HbAlc was 9.8%, urinary CPR was 81.2 |ig/ day, and serum IRI was 7 jiU/ml. Metoformin and voglibose were prescribed and HbAlcwas decreased to 6.8% in May, but the effect of these drugs was temporary. In November, HbA,c was 8.6% and troglitazone was added. Her HbA,c decreased. Her HbA,c increased again when troglitazone was discontinued, but it was improved when MPAadministration was discontinued. These two patients showed deterioration of blood glucose control after MPAadministration. The effects of sulphonylurea, biganide, and oc-glucosidase inhibitor were insufficient. During treatment with MPA, side effects due to glucocorticoid activity have been reported, including weight gain, moon face, hypertension, fluid retention, and hyperglycemia ( 1). Steroid-induced diabetic patients often require insulin treatment. Regarding the glucocorticoidinduced insulin resistance, troglitazone prevented the decrease in insulin-stimulated glucose disposal, namely the development of peripheral insulin resistance, and not the hepatic glucose output in dexamethasone-treated rats (3).
